Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Acta Pharmacol Sin. 2015 Oct;36(10):1163-9. doi: 10.1038/aps.2015.68. Epub 2015 Aug 24.

Toward rapamycin analog (rapalog)-based precision cancer therapy.

Author information

1
Rutgers Cancer Institute of New Jersey and Division of Cancer Pharmacology, Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, New Brunswick, NJ 08903, USA.
2
Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Abstract

Rapamycin and its analogs (rapalogs) are the first generation of mTOR inhibitors, which have the same molecular scaffold, but different physiochemical properties. Rapalogs are being tested in a wide spectrum of human tumors as both monotherapy and a component of combination therapy. Among them, temsirolimus and everolimus have been approved for the treatment of breast and renal cancer. However, objective response rates with rapalogs in clinical trials are modest and variable. Identification of biomarkers predicting response to rapalogs, and discovery of drug combinations with improved efficacy and tolerated toxicity are critical to moving this class of targeted therapeutics forward. This review focuses on the aberrations in the PI3K/mTOR pathway in human tumor cells or tissues as predictive biomarkers for rapalog efficacy. Recent results of combinational therapy using rapalogs and other anticancer drugs are documented. With the rapid development of next-generation genomic sequencing and precision medicine, rapalogs will provide greater benefits to cancer patients.

PMID:
26299952
PMCID:
PMC4648176
DOI:
10.1038/aps.2015.68
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center